Piling on to Theranos woes, the Securities and Exchange Commission and the U.S. Attorney's Office for the Northern District of California have started probing into the blood analysis startup for possible criminal activity. The microscope under which Theranos found itself for regulatory health and safety issues over the last year prompted both agencies to question operations. Theranos sent… Read More
Source: TechCrunch